IL248948B - - α3hydroxy--β3-methoxymethyl-5)-21-methyl-2h-tetrazole-2-yl-19-nor-α5-paragnane-20-one and its pharmaceutical preparation - Google Patents

- α3hydroxy--β3-methoxymethyl-5)-21-methyl-2h-tetrazole-2-yl-19-nor-α5-paragnane-20-one and its pharmaceutical preparation

Info

Publication number
IL248948B
IL248948B IL248948A IL24894816A IL248948B IL 248948 B IL248948 B IL 248948B IL 248948 A IL248948 A IL 248948A IL 24894816 A IL24894816 A IL 24894816A IL 248948 B IL248948 B IL 248948B
Authority
IL
Israel
Prior art keywords
mmol
compound
solution
added
synthesis
Prior art date
Application number
IL248948A
Other languages
English (en)
Hebrew (he)
Other versions
IL248948A0 (en
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of IL248948A0 publication Critical patent/IL248948A0/en
Publication of IL248948B publication Critical patent/IL248948B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003Androstane derivatives
    • C07J1/0018Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0059Estrane derivatives substituted in position 17 by a keto group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J13/00Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL248948A 2014-05-29 2015-05-29 - α3hydroxy--β3-methoxymethyl-5)-21-methyl-2h-tetrazole-2-yl-19-nor-α5-paragnane-20-one and its pharmaceutical preparation IL248948B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014078820 2014-05-29
PCT/CN2015/080216 WO2015180679A1 (en) 2014-05-29 2015-05-29 Neuroactive steroids, compositions, and uses thereof

Publications (2)

Publication Number Publication Date
IL248948A0 IL248948A0 (en) 2017-01-31
IL248948B true IL248948B (en) 2022-09-01

Family

ID=54698130

Family Applications (3)

Application Number Title Priority Date Filing Date
IL248948A IL248948B (en) 2014-05-29 2015-05-29 - α3hydroxy--β3-methoxymethyl-5)-21-methyl-2h-tetrazole-2-yl-19-nor-α5-paragnane-20-one and its pharmaceutical preparation
IL292461A IL292461B2 (en) 2014-05-29 2015-05-29 3?-hydroxy-3?-methoxymethyl-21-(5-methyl-2H-tetrazol-2-yl)-19-nor-5?-paragenan-20-one for use in a method for treating disorders related to the central nervous system
IL304033A IL304033A (en) 2014-05-29 2015-05-29 Neuroactive steroids, preparations and their uses

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL292461A IL292461B2 (en) 2014-05-29 2015-05-29 3?-hydroxy-3?-methoxymethyl-21-(5-methyl-2H-tetrazol-2-yl)-19-nor-5?-paragenan-20-one for use in a method for treating disorders related to the central nervous system
IL304033A IL304033A (en) 2014-05-29 2015-05-29 Neuroactive steroids, preparations and their uses

Country Status (26)

Country Link
US (5) US20180179247A1 (da)
EP (3) EP4144746A1 (da)
JP (4) JP6652934B2 (da)
KR (3) KR20240066304A (da)
CN (3) CN114369135A (da)
AR (2) AR100691A1 (da)
AU (4) AU2015266447A1 (da)
CA (1) CA2949720A1 (da)
CY (1) CY1124109T1 (da)
DK (2) DK3149018T3 (da)
ES (2) ES2805598T3 (da)
HR (2) HRP20221294T1 (da)
HU (2) HUE059829T2 (da)
IL (3) IL248948B (da)
JO (1) JO3691B1 (da)
LT (2) LT3149018T (da)
MX (4) MX2016015532A (da)
PH (1) PH12016502342A1 (da)
PL (2) PL3149018T3 (da)
PT (2) PT3149018T (da)
RS (2) RS60529B1 (da)
RU (2) RU2699359C2 (da)
SG (2) SG10201803812TA (da)
SI (2) SI3149018T1 (da)
TW (1) TW201625661A (da)
WO (1) WO2015180679A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006318349B2 (en) 2005-11-28 2010-08-19 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
ES2738526T3 (es) 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
SG11201508550XA (en) 2013-04-17 2015-11-27 Sage Therapeutics Inc 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
CA2909546C (en) 2013-04-17 2019-01-22 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
SI3021852T1 (sl) 2013-07-19 2021-07-30 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporabe le-teh
EP3035940B1 (en) 2013-08-23 2018-10-17 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
SG10201803812TA (en) * 2014-05-29 2018-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
SG10202009861SA (en) 2014-10-16 2020-11-27 Sage Therapeutics Inc Compositions and methods for treating cns disorders
PL3206493T3 (pl) 2014-10-16 2021-01-25 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
LT3224269T (lt) 2014-11-27 2020-07-10 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti cns sutrikimams gydyti
PL3250210T3 (pl) 2015-01-26 2021-07-26 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
CA3001722A1 (en) 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
MA43815A (fr) * 2016-03-08 2021-04-07 Sage Therapeutics Inc Stéroïdes neuroactifs, compositions, et leurs utilisations
CN116162121A (zh) * 2016-07-11 2023-05-26 萨奇治疗股份有限公司 C17、c20和c21取代的神经活性类固醇及其使用方法
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2019113494A1 (en) 2017-12-08 2019-06-13 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
CA3090724A1 (en) * 2018-02-11 2019-08-15 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
CN109503694A (zh) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CA3124703C (en) * 2019-01-14 2023-10-17 Beijing Xuanyi Pharmasciences Co., Ltd. Tetrazolone substituted steroids and use thereof
MX2021014515A (es) 2019-05-31 2022-03-22 Sage Therapeutics Inc Esteroides neuroactivos y composiciones de estos.
WO2021026124A1 (en) 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
KR20220066262A (ko) 2019-08-07 2022-05-24 상하이 한서 바이오메디컬 컴퍼니 리미티드 스테로이드 유도체 조절제의 염 및 결정형
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
JP2023503928A (ja) 2019-12-06 2023-02-01 マリナス ファーマシューティカルズ, インコーポレイテッド 結節性硬化症の治療での使用のためのガナキソロン
US20240122945A1 (en) 2021-01-28 2024-04-18 Sage Therapeutics, Inc. Use of neuroactive steroids for treatment of sexual dysfunction
BR112024001518A2 (pt) * 2021-07-28 2024-04-30 Sage Therapeutics Inc Formas cristalinas de um esteroide neuroativo
WO2023164387A1 (en) 2022-02-28 2023-08-31 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions
WO2024026337A1 (en) 2022-07-27 2024-02-01 Sage Therapeutics, Inc. Crystalline forms of a neuroactive steroid
WO2024059608A1 (en) 2022-09-15 2024-03-21 Sage Therapeutics, Inc. Deuterated neuroactive steroids

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013056181A1 (en) * 2011-10-14 2013-04-18 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3634717A1 (de) * 1986-10-11 1988-04-14 Dynamit Nobel Ag Verfahren zur herstellung von 5-methyltetrazol
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
FR2679263B1 (fr) * 1991-07-15 1994-01-14 Staubli Ets Perfectionnements aux ratieres a double leve du type hattersley pour machines a tisser.
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
DE69518509T2 (de) * 1994-02-14 2001-04-19 Euro Celtique Sa Androstane und pregnane zur allosterischen modulation des gaba-rezeptors
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
UA73736C2 (en) * 1999-04-29 2005-09-15 Euro Celtic S A Method for alleviating or preventing insomnia and inducing anesthesia
WO2004036372A2 (en) * 2002-10-15 2004-04-29 Medtronic Inc. Scoring of sensed neurological signals for use with a medical device system
US7729773B2 (en) * 2005-10-19 2010-06-01 Advanced Neuromodualation Systems, Inc. Neural stimulation and optical monitoring systems and methods
SG10201803812TA (en) * 2014-05-29 2018-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
PL3206493T3 (pl) * 2014-10-16 2021-01-25 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013056181A1 (en) * 2011-10-14 2013-04-18 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof

Also Published As

Publication number Publication date
AR100691A1 (es) 2016-10-26
AU2015266447A1 (en) 2016-12-01
CN114133423A (zh) 2022-03-04
PH12016502342A1 (en) 2017-02-13
RS63554B1 (sr) 2022-09-30
SG10201803812TA (en) 2018-06-28
JP2023123878A (ja) 2023-09-05
JP2017516793A (ja) 2017-06-22
US20240076310A1 (en) 2024-03-07
HRP20221294T1 (hr) 2023-03-03
NZ726260A (en) 2023-11-24
JP6652934B2 (ja) 2020-02-26
HRP20201126T1 (hr) 2020-12-11
CN106661078A (zh) 2017-05-10
KR102494061B1 (ko) 2023-01-31
EP4144746A1 (en) 2023-03-08
PL3149018T3 (pl) 2021-01-25
CN114369135A (zh) 2022-04-19
RU2016151727A3 (da) 2018-12-03
SI3705488T1 (sl) 2022-10-28
US20200165291A1 (en) 2020-05-28
WO2015180679A1 (en) 2015-12-03
AU2019279910B2 (en) 2021-07-22
US20210061849A1 (en) 2021-03-04
KR20240066304A (ko) 2024-05-14
IL248948A0 (en) 2017-01-31
RU2699359C2 (ru) 2019-09-05
KR102664412B1 (ko) 2024-05-21
ES2805598T3 (es) 2021-02-12
IL292461A (en) 2022-06-01
AR121661A2 (es) 2022-06-29
MX2023004352A (es) 2023-05-08
AU2019279910A1 (en) 2020-01-16
JP6892936B2 (ja) 2021-06-23
LT3149018T (lt) 2020-08-10
KR20230021165A (ko) 2023-02-13
SG11201609813XA (en) 2016-12-29
AU2021204410B2 (en) 2023-09-21
EP3149018B1 (en) 2020-04-29
US20210061850A1 (en) 2021-03-04
BR112016027508A2 (pt) 2018-06-26
IL292461B1 (en) 2023-11-01
JP2020073577A (ja) 2020-05-14
JP7386204B2 (ja) 2023-11-24
EP3705488A1 (en) 2020-09-09
DK3149018T3 (da) 2020-07-20
SI3149018T1 (sl) 2020-10-30
JP2021130696A (ja) 2021-09-09
PT3705488T (pt) 2022-09-30
TW202231652A (zh) 2022-08-16
LT3705488T (lt) 2022-09-26
ES2927007T3 (es) 2022-10-31
HUE059829T2 (hu) 2022-12-28
NZ764941A (en) 2023-11-24
AU2021204410A1 (en) 2021-07-22
MX2021005106A (es) 2021-06-15
IL292461B2 (en) 2024-03-01
MX2021005099A (es) 2021-06-15
RU2016151727A (ru) 2018-07-02
AU2023285755A1 (en) 2024-01-18
CA2949720A1 (en) 2015-12-03
PL3705488T3 (pl) 2022-12-05
US20180179247A1 (en) 2018-06-28
DK3705488T3 (da) 2022-10-03
JO3691B1 (ar) 2020-08-27
TW201625661A (zh) 2016-07-16
CY1124109T1 (el) 2022-03-24
HUE050028T2 (hu) 2021-12-28
RS60529B1 (sr) 2020-08-31
EP3705488B1 (en) 2022-08-03
MX2016015532A (es) 2017-02-27
KR20170003706A (ko) 2017-01-09
NZ764921A (en) 2023-11-24
RU2019126637A (ru) 2019-10-03
EP3149018A4 (en) 2017-12-06
IL304033A (en) 2023-08-01
EP3149018A1 (en) 2017-04-05
PT3149018T (pt) 2020-07-21

Similar Documents

Publication Publication Date Title
AU2021204410B2 (en) Neuroactive steroids, compositions, and uses thereof
AU2020256400B2 (en) 19-Nor C3,3-Disubstituted C21-N-Pyrazolyl Steroids And Methods Of Use Thereof
WO2015195962A1 (en) Neuroactive steroids, compositions, and uses thereof
IL293231A (en) Oxysterols and methods of using them
WO2014169836A1 (en) 19-nor neuroactive steroids and methods of use thereof
TWI839649B (zh) 神經活性類固醇,其組合物及其用途
BR112016027508B1 (pt) Composto esteróide neuroativo, seu sal, composição farmacêutica, seus usos e processo para preparar o composto